Navigation Links
CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
Date:5/26/2009

VIENNA, Va. May 26 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it is developing an immune-based treatment for the "swine flu and related H1N1" flu viruses, utilizing its proprietary L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology. The Company plans to utilize the expertise and knowledge it has gained from developing protective and therapeutic vaccines utilizing L.E.A.P.S. to develop a therapeutic treatment based upon the technology for people infected with the swine and H1N1 flu viruses. CEL-SCI has already commenced pre-clinical testing.

Previously, CEL-SCI announced that its CEL-1000 peptide, which is derived from the L.E.A.P.S. technology, showed adjuvant activity when used with a peptide based malaria vaccine and a DNA based malaria vaccine in animal challenge studies as part of a Cooperative Research arrangement with the Naval Medical Research Center, Silver Spring, MD. In both cases, the addition of CEL-1000 to the vaccines resulted in significant increases in the protection of the animals. In addition, several different L.E.A.P.S. conjugates induced protection and/or improvement in diseases as diverse as rheumatoid arthritis, malaria, TB and herpes simplex viruses. This shows that the L.E.A.P.S. technology can be successfully applied to many different diseases and these results further suggest that L.E.A.P.S. has the potential to be used either alone as a therapy or as an adjuvant to vaccines under development for the treatment of H1N1 related flu viruses. Adjuvants are designed to improve the effectiveness of vaccines.

"We believe that our L.E.A.P.S. technology platform offers strong potential to address the current swine and H1N1 flu viruses," said Dr. Daniel Zimmerman of CEL-SCI, the inventor of the technology. "With the swine flu currently cr
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
2. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
3. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
4. CEL-SCI Corporation Announces 2008 Financial Results
5. CEL-SCI Corporation Releases Letter to Shareholders
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Takes Delivery of New Manufacturing Facility
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
10. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
11. CEL-SCI to Present at the Noble Financial Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--DowAgroSciencesCana...s,adivisionofThompsonsLimitedofBlenheim,Ontario.Th...nces,currentseedsbusinessasthecompanyanticipatesth...SciencesHerbicideTolerantTraitTechnologyincornin20... ,, "Thisacquisitionbringstogethertwostrongprog...
(Date:11/24/2009)...-Asia/--NODPharmaceuticalsInc.announced,theUSPaten...cationfor,itsnano-particleoraldeliveryorNODtechnol...htoincorporatepeptidesor,proteinsintobio-adhesiven...administeredasinjections.NODtechnologyisaplatformt...ssuchasinsulin,interferon,growthhormone,exenatide...
(Date:11/24/2009)...beenmetforpatientswithadvanced-stage,orrecurrenten...re-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TS...nyfocusedonendocrinetherapyandoncology,todayannoun...etedcytotoxicpeptideconjugate,AEZS-108(formerlyAN-...ancer.Inapersonalizedhealthcareapproach,thestudyse...
(Date:11/24/2009)...ewswire/--HealthRoboticstodayannounced,thatithasfo...nvestors.ThisrecentlyformedToronto-basedcompanywil...illmarket,install,andsupport,HealthRobotics,i.v.Ro...yproductofferingsi.v.STATION(TM),i.v.SOFT(TM),andO...istanceonan"asneeded,basis"toitsstrategicpartnersh...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...h Park MADISON OpGen, Inc. has added two new me...omas Pyle. The company is looking to bring in seas...he next level, according to Dan Broderick, managin... , ,They bring lots of experience with company ope...hey have long, successful careers in business and ...
...y figures show no reported venture investment acti...ear. Both total venture capital and initial ventur...as released by PricewaterhouseCoopers, Thomson Ven...sociation. Ten other states also showed $0 activit...money, according to the survey, with California re...
...ializing in patient-specific molecular data and pe...ts president and chief executive officer, it annou...esident and CEO of Pel-Freez Clinical Systems , l...ar biology and serologic products for solid organ ...icant growth and eventual acquisition under Langel...
Other Biology Technology:OpGen adds Thomas Pyle and James Ogle to board of directors 2MoneyTree Survey reports no venture investment activity in Wisconin in Q2 2MoneyTree Survey reports no venture investment activity in Wisconin in Q2 3MoneyTree Survey reports no venture investment activity in Wisconin in Q2 4MoneyTree Survey reports no venture investment activity in Wisconin in Q2 5MoneyTree Survey reports no venture investment activity in Wisconin in Q2 6
(Date:11/24/2009)... atomic-level action of a remarkable class of ring...rchers with the Lawrence Berkeley National Laborat...n crystallography beamline at the Advanced Light S...es in gene expression and replication, and are vit...l as infectious agents, such as the human papillom...
(Date:11/24/2009)...at constitutes fish food is a matter of debate. A ...fish get almost 50 percent of their carbon from tr...ween the terrestrial and aquatic ecosystems. , B...shows this is not likely to be true. Algae provide...e, according to research published this week in th...
(Date:11/23/2009)...hington, D.C. The community-associated strain of ...ria resistant to most common antibioticsposes a fa...is making its way into hospitals, according to a s... Diseases . , The new threat is easily picked u...aces and has increased the overall burden of MRSA ...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 1IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 2IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 3IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 4Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 1Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 2Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 3BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 1BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 2BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 3BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 4
...T LAFAYETTE, Ind. - Chemical engineers have develo...an inexpensive way of making diamondlike crystals ...logies. , The method, developed at Purdue Univers...licon template containing precisely spaced holes t...air. The template is immersed in water on top of w...
...orld was in shock when in 2001 the Talibans destro...han region of Bamiyan. Behind those statues, there...5th to 9th century A.D. The caves also suffered fr...atural environment, but today they have become the...ed, thanks to experiments performed at the Europea...
...er twenty-five years of investigating, analyzing, ...ers, neighbors, and even surviving victims, crimin...of the worlds most respected experts on the motiva...n SERIAL KILLERS AND SADISTIC MURDERERS: UP CLOSE ...is wealth of experience with the criminal mind to ...
Other Biology News:Findings a step toward making new optical materials 2Findings a step toward making new optical materials 3Findings a step toward making new optical materials 4Findings a step toward making new optical materials 5Synchrotron light unveils oil in ancient Buddhist paintings from Bamiyan 2A chilling glimpse inside the minds of dangerous criminals 2
Acridine orange, hemizinc salt from Research Organics, Inc.
Acridine orange 10-nonyl bromide from AnaSpec
Anti-rat Ig HRP detection kit from BD Biosciences Pharmingen
Wash Solution from CHEMICON
Biology Products: